Michael McElhaugh
Chief Executive Officer bij ARBUTUS BIOPHARMA CORPORATION
Vermogen: 3 M $ op 31-03-2024
Profiel
Mr. Michael J.
McElhaugh is a President & Chief Executive Officer at Arbutus Biopharma, Inc. and a President, Chief Executive Officer, COO & Director at Arbutus Biopharma Corp.
He is on the Board of Directors at Arbutus Biopharma Corp.
Mr. McElhaugh was previously employed as a Director-Business Development by Pharmasset, Inc. and a Director-Hepatitis C Worldwide Commercialization by Bristol Myers Squibb Co. He received his undergraduate degree from St. Joseph's University, a graduate degree from Thomas Jefferson University and an MBA from Johnson Graduate School of Management.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 25-03-2024 | 1 325 193 ( 0.74% ) | 3 M $ | 31-03-2024 |
Actieve functies van Michael McElhaugh
| Bedrijven | Functie | Begin |
|---|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Chief Executive Officer | 01-01-2024 |
Arbutus Biopharma, Inc.
 Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Chief Executive Officer | 01-01-2024 |
Eerdere bekende functies van Michael McElhaugh
| Bedrijven | Functie | Einde |
|---|---|---|
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Corporate Officer/Principal | 01-03-2012 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Arbutus Biopharma, Inc.
Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Founder | - |
Opleiding van Michael McElhaugh
| Thomas Jefferson University | Graduate Degree |
| St. Joseph's University | Undergraduate Degree |
| Johnson Graduate School of Management | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ARBUTUS BIOPHARMA CORPORATION | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Pharmasset, Inc.
Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Health Technology |
Arbutus Biopharma, Inc.
Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Health Technology |
